SL-22P is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Refractory Brain Metastasis. According to GlobalData, Phase I drugs for Refractory Brain Metastasis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SL-22P LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SL-22P overview

SL-22P is under development for the treatment of solid tumours including refractory brain metastasis, and liver cancer. It comprises of autologous T-cells genetically engineered to express chimeric antigen receptor (CAR-T) targeting the cells expressing CD22 and armoured with anti-PD-L1. It is administered by parenteral route.

Hebei Senlang Biotechnology overview

Hebei Senlang Biotechnology is a pharamaceutial and healthcare company which is involved in using bio technology for treatment of immune cells. The company is headquartered in Dongguan, Hebei, China.

For a complete picture of SL-22P’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.